Asymptomatic Inflammatory Bowel Disease Diagnosed During Colorectal Cancer Population Screening in Catalonia: Characteristics and Natural History
Por:
Brunet-Mas, E, Selva, A, Bas-Cutrina, F, Brujats, A, Caballol, B, Font, R, Gómez, B, Gonzalez-Muñosa, C, Busquets, D, Monfort, D, Vera, DP, Maristany, E, Cirera, G, Torres, G, Castro-Poceiro, J, Lopez, J, Gonzalez-Gonzalez, L, Márquez-Mosquera, L, Gallach, M, Esteve, M, Tremosa, G, Torra, S, Robles-Alonso, V, Garcia-Iglesias, P, Rodríguez-Lago, I, Calvet, X
Publicada:
1 feb 2025
Resumen:
INTRODUCTION:Inflammatory bowel disease (IBD) is usually diagnosed when symptomatic. Prognosis and evolution of preclinical IBD is largely unknown. However, colorectal cancer screening programs (CRCSP) detect a subset of patients with IBD with no symptoms. The aim of this study was to describe the natural history of asymptomatic IBD diagnosed through CRCSP. METHODS:An observational, longitudinal, and retrospective study was performed at 22 centers in Catalonia between January 2010 and December 2019 including patients with asymptomatic IBD detected in the CRCSP. Demographic data and IBD characteristics, evolution, and treatment were recorded. Descriptive statistics and Kaplan-Meier analysis were used for the analysis. Data were given separately for IBD, Crohn's disease (CD), ulcerative colitis (UC), and IBD unclassified (IBDU). RESULTS:One hundred eighty-eight patients were included: 103 UC (54.8%), 60 CD (31.9%), and 25 IBDU (13.3%). Sixty-six (35.1%) were women, and the average age was 59.9 +/- 5.9 years. Sixty-four patients (34.0%) developed symptoms after a median follow-up of 35.6 months. Diarrhea was the most frequent symptom for CD and IBDU (25.4% and 11.5%, respectively) and blood in stools for UC (21.4%). The median time to first symptom was 11.6 months. Treatment was prescribed in 135 patients (72.2%); mesalazine was the most prescribed drug (123 patients; 65.4%). Thirteen patients (6.9%) required biological treatment. None underwent surgery. DISCUSSION:Around one-third of asymptomatic patients with IBD developed symptoms after a medium follow-up of 3 years. Only 6.9% required biological treatment, and none required surgery. Overall, prognosis of asymptomatic IBD seems better.
Filiaciones:
Brunet-Mas, E:
Parc Tauli Hosp Univ, Inst Invest & Innovacio Parc Tauli I3PT CERCA, Gastroenterl Dept, Sabadell, Spain
Univ Autonoma Barcelona, Dept Med, Barcelona, Spain
Inst Salud Carlos III, CIBERehd, Madrid, Spain
Selva, A:
Univ Autonoma Barcelona, Parc Tauli Hosp Univ, Inst Invest & Innovacio Parc Tauli I3PT CERCA, Clin Epidemiol & Canc Screening, Barcelona, Spain
Univ Autonoma Barcelona, Dept Pediat Obstet Gynecol & Prevent Med, Barcelona, Spain
Inst Salud Carlos III, CIBER Epidemiol & Salud Publ, Madrid, Spain
Bas-Cutrina, F:
Hosp Gen Granollers, Gastroenterol Dept, Granollers, Spain
Brujats, A:
Hosp Berga Salut Catalunya Cent, Gastroenterol Dept, Berga, Spain
Hosp Santa Creu & St Pau Barcelona, Gastroenterol Dept, Barcelona, Spain
Caballol, B:
Hosp Clin Barcelona, Inst Invest Biomed Pi Sunyer IDIBAPS, Gastroenterol Dept, CIBEREHD, Barcelona, Spain
Font, R:
Catalan Canc Plan, Dept Hlth, Barcelona, Spain
Bellvitge Biomed Res Inst IDIBELL, Barcelona, Spain
Gómez, B:
Hosp Mataro, Gastroenterol Dept, Mataro, Spain
Gonzalez-Muñosa, C:
Hosp Santa Creu & St Pau Barcelona, Gastroenterol Dept, Barcelona, Spain
Busquets, D:
Hosp Univ Girona Dr J Trueta, Gastroenterol Dept, Girona, Spain
Monfort, D:
Consorci Sanitari Terrassa, Gastroenterol Dept, Terrassa, Spain
Vera, DP:
Hosp Martorell, Gastroenterol Dept, Martorell, Spain
Maristany, E:
Hosp Bellvitge Princeps Espanya, Gastroenterol Dept, Barcelona, Spain
Cirera, G:
Hosp Althaia, Gastroenterol Dept, Manresa, Spain
Torres, G:
Hosp Arnau Vilanova, Gastroenterol Dept, Lleida, Spain
Castro-Poceiro, J:
Hosp Moises Broggi St Joan Despi, Gastroenterol Dept, Barcelona, Spain
Lopez, J:
Hosp Univ Joan XXIII, Gastroenterol Dept, Tarragona, Spain
Gonzalez-Gonzalez, L:
Hosp Germans Tries & Pujol, Gastroenterol Dept, Badalona, Spain
Márquez-Mosquera, L:
Hosp Mar, Gastroenterol Dept, Barcelona, Spain
Gallach, M:
Hosp Univ Vic, Gastroenterol Dept, Vic, Spain
Esteve, M:
Inst Salud Carlos III, CIBERehd, Madrid, Spain
Hosp Univ Mutua Terrassa, Gastroenterol Dept, Terrassa, Spain
Tremosa, G:
Hosp Comarcal Alt Penedes, Gastroenterol Dept, Barcelona, Spain
Torra, S:
Parc Sanitari St Joan Deu, Gastroenterol Dept, Barcelona, Spain
Robles-Alonso, V:
Hosp Valle De Hebron, Gastroenterol Dept, Barcelona, Spain
Garcia-Iglesias, P:
Hosp Igualada, Gastroenterol Dept, Igualada, Spain
Rodríguez-Lago, I:
Univ Deusto, Hosp Univ Galdakao, Biobizkaia Hlth Res Inst, Gastroenterol Dept, Galdakao, Spain
Calvet, X:
Parc Tauli Hosp Univ, Inst Invest & Innovacio Parc Tauli I3PT CERCA, Gastroenterl Dept, Sabadell, Spain
Univ Autonoma Barcelona, Dept Med, Barcelona, Spain
Inst Salud Carlos III, CIBERehd, Madrid, Spain
Univ Autonoma Barcelona, Med Dept, Bellaterra, Spain
Green Submitted, gold
|